Allara raises $30 million to expand AI-enabled care đź’¸
‍
Allara has announced $30 million in new funding, bringing its total funding to $75 million. The company plans to invest in clinician-supporting AI tools, expand healthcare partnerships and advance research across hormonal, metabolic and reproductive health. Existing investors including Index Ventures and GV increased their commitments, alongside new investors Camino Partners, Foreground Capital and Family Fund.
‍
"Allara is delivering an exceptional care experience for women whose complex needs have fallen through the cracks in the traditional healthcare system."
— Elle Lanning, President at Camino Partners
‍
‍
‍
‍
‍
Unravel Health announces €2.96 million round for at-home hormone testing 🏡
‍
London-based Unravel Health has announced a €2.96 million (£2.5 million) funding round to develop its Micro Lab, a palm-sized device designed to measure multiple hormones from saliva. Led by Conduit EIS Impact Fund and Wrightwood, the round will support external equivalency studies, additional markers and the start of the regulatory approval process. We are proud to say that Unravel Health won our pitch competition at this year's Women's Sports Summit!
‍
“People said nobody could climb Everest without oxygen, until someone did. Reading hormones in saliva outside a lab has been our Everest. Fifteen years ago I built my own hormone tracker to manage PCOS (now PMOS), because a blood test told me almost nothing about what my body was doing. Soon anyone will be able to bring the lab home to understand their symptoms.”
— Veronika Bridgman, co-founder and CEO, Unravel Health
‍
‍
‍
‍
‍
Fuwo secures funding for oral breast cancer drug trials đź’Š
‍
Shenzhen Fuwo Pharmaceutical has closed a new funding round to advance FWD1802, its investigational oral selective oestrogen receptor degrader. The capital will support a Phase III registrational trial, Phase Ib/II combination studies and other pipeline programmes. Backers include funds linked to Wuhan Hi-Tech State-owned Holding Group and Wuhan Innovation Investment Group, alongside TG Sino-Dragon Fund II. The round size was not disclosed in the supplied report.
‍
‍
‍
‍
‍
Hologic signs agreement to acquire Reveal Genomics đź’Ş
‍
Hologic has signed a definitive agreement to acquire Barcelona-based Reveal Genomics, adding precision oncology capabilities to its breast cancer diagnostics portfolio. Reveal’s HER2DX test supports treatment decisions for HER2-positive breast cancer and would complement Hologic’s Breast Cancer Index offering.
‍
“Reveal Genomics’ portfolio is a strong strategic complement to our existing oncology offering within Diagnostic Solutions and would allow us to support even more women diagnosed with breast cancer."
— Vitor Rocha, CEO of Diagnostic Solutions at Hologic
‍
‍
‍
‍
‍
Roche and Bright Future Fund launch Vietnam screening campaign 🔎
‍
Roche Pharma Vietnam and the Bright Future Fund have launched the 2026 edition of “Joining Hands for Her”. The campaign combines breast cancer awareness with free screening for women at higher risk. According to the announcement, the partnership has supported screening for more than 80,000 women and training for 600 healthcare professionals since 2013.
‍
“Roche Pharma Vietnam has been honoured to partner with the Bright Future Fund on this campaign for the past 13 years. This experience has clearly demonstrated that greater awareness and routine screening can transform breast cancer treatment. As a global leader in healthcare, Roche is committed to remaining a reliable, long-term partner of Vietnam's health sector, so that every diagnosis represents a genuine opportunity for a Vietnamese woman.”
— Burak Pekmezci, General Manager, Roche Pharma Vietnam
‍
‍
‍
‍
